Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,416 | -24,579 | -20,090 | -12,773 | -9,375 |
| Depreciation Amortization | 62 | 497 | 411 | 290 | 138 |
| Accounts receivable | 304 | -262 | -237 | -5 | -146 |
| Other Working Capital | -1,480 | 3,710 | 4,053 | 2,604 | 399 |
| Other Operating Activity | 481 | -342 | 322 | 459 | 3,552 |
| Operating Cash Flow | $-6,049 | $-20,976 | $-15,541 | $-9,425 | $-5,432 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -47 | -176 | -133 | -46 |
| Investing Cash Flow | $0 | $-47 | $-176 | $-133 | $-46 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -2 | -1 | N/A | N/A |
| Common Stock Issued | N/A | 19,713 | 12,000 | 11,993 | 11,993 |
| Dividend Paid | N/A | -16 | -8 | -8 | N/A |
| Other Financing Activity | 0 | -116 | -5 | -5 | 0 |
| Financing Cash Flow | $0 | $19,579 | $11,986 | $11,980 | $11,993 |
| Beginning Cash Position | 15,541 | 16,985 | 16,985 | 16,985 | 16,985 |
| End Cash Position | 9,492 | 15,541 | 13,254 | 19,407 | 23,500 |
| Net Cash Flow | $-6,049 | $-1,444 | $-3,731 | $2,422 | $6,515 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,049 | -20,976 | -15,541 | -9,425 | -5,432 |
| Capital Expenditure | N/A | -297 | -276 | -233 | -46 |
| Free Cash Flow | -6,049 | -21,273 | -15,817 | -9,658 | -5,478 |